UY27220A1 - Combinación de un taxano con una quinasa ciclina-dependiente - Google Patents

Combinación de un taxano con una quinasa ciclina-dependiente

Info

Publication number
UY27220A1
UY27220A1 UY27220A UY27220A UY27220A1 UY 27220 A1 UY27220 A1 UY 27220A1 UY 27220 A UY27220 A UY 27220A UY 27220 A UY27220 A UY 27220A UY 27220 A1 UY27220 A1 UY 27220A1
Authority
UY
Uruguay
Prior art keywords
dependent kinase
taxan
cycline
combination
cyclin
Prior art date
Application number
UY27220A
Other languages
English (en)
Spanish (es)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY27220A1 publication Critical patent/UY27220A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY27220A 2001-03-23 2002-03-21 Combinación de un taxano con una quinasa ciclina-dependiente UY27220A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04

Publications (1)

Publication Number Publication Date
UY27220A1 true UY27220A1 (es) 2002-09-30

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27220A UY27220A1 (es) 2001-03-23 2002-03-21 Combinación de un taxano con una quinasa ciclina-dependiente

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487434B1 (en) * 2002-03-06 2007-05-09 The Medical Research and Education Trust Botanical extract compositions with anti-cancer activity comprising isoliquiritigenin
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
JP4764165B2 (ja) * 2002-11-06 2011-08-31 サイクラセル リミテッド ドセタキセル及びcdk阻害剤を含む組合せ
EP1986632B1 (en) * 2006-02-10 2012-08-15 Nerviano Medical Sciences S.R.L. Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
JP6080837B2 (ja) * 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
KR100879712B1 (ko) 2009-01-22
JP2004521140A (ja) 2004-07-15
CZ20032551A3 (en) 2004-07-14
YU69503A (sh) 2006-08-17
TWI355935B (en) 2012-01-11
PE20020907A1 (es) 2002-12-19
CA2441441C (en) 2009-05-26
DE60226710D1 (de) 2008-07-03
ZA200307381B (en) 2005-03-30
NO20034124D0 (no) 2003-09-16
NO20034124L (no) 2003-09-16
CN1498107A (zh) 2004-05-19
EP1372652A2 (en) 2004-01-02
MEP16408A (en) 2010-10-10
PL367702A1 (en) 2005-03-07
SK11692003A3 (sk) 2004-03-02
BR0208221A (pt) 2004-03-02
NZ527655A (en) 2006-03-31
AR034222A1 (es) 2004-02-04
SK287481B6 (sk) 2010-11-08
HUP0303589A2 (hu) 2004-03-01
IL158058A (en) 2010-02-17
ATE395917T1 (de) 2008-06-15
WO2002076484A2 (en) 2002-10-03
MXPA03007743A (es) 2004-11-12
CZ301423B6 (cs) 2010-02-24
CA2441441A1 (en) 2002-10-03
HRP20030766A2 (en) 2005-06-30
IL158058A0 (en) 2004-03-28
AU2002312815B2 (en) 2006-08-24
US20020182204A1 (en) 2002-12-05
WO2002076484A3 (en) 2003-01-03
EA007815B1 (ru) 2007-02-27
HRPK20030766B3 (en) 2006-11-30
EA200301053A1 (ru) 2004-02-26
RS50681B (sr) 2010-06-30
HUP0303589A3 (en) 2007-05-02
CY1110449T1 (el) 2015-04-29
ES2305253T3 (es) 2008-11-01
SI1372652T1 (sl) 2008-10-31
EP1372652B1 (en) 2008-05-21
US20060128640A1 (en) 2006-06-15
PL206118B1 (pl) 2010-07-30
DK1372652T3 (da) 2008-09-22
NO332441B1 (no) 2012-09-17
KR20030086318A (ko) 2003-11-07
HU229258B1 (en) 2013-10-28
PT1372652E (pt) 2008-07-24

Similar Documents

Publication Publication Date Title
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
AR109263A2 (es) Composición que comprende moxidectina
DE60203260D1 (de) Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
CY1110449T1 (el) Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
UY27018A1 (es) Derivados de la pirimidina
AR022588A1 (es) Derivados de mevinolina
AR039232A1 (es) Una formulacion farmaceutica que comprende al menos un compuesto seleccionado del grupo formado por hipnoticos no barbituricos y no benzodiacepinicos, y melatonina
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
ECSP089024A (es) Camsilato de (s)-(-)-amlodipino o hidrato del mismo y composición farmacéutica que comprende el mismo
CR8948A (es) Composicion farmaceutica
DE60312642D1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
AR062375A1 (es) Cristal de epotilona b y composiciones farmaceuticas
EA200601632A1 (ru) Новая комбинация гетероциклического соединения и антиоксиданта и фармацевтические композиции, которые её содержат

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141126